Skip to content
Open access · CC-BY via OpenAlex

Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study

Kristin L. Dawson, Athena May Jean M. Carangan, Jessica Klunder, Natàlia Carreras-Gallo, Raghav Sehgal, Samantha Megilligan, Benjamin C. Askins, Nicole Perkins, Tavis L. Mendez, Ryan M. Smith, Mark G. Dawson, Michael P. Mallin, Albert Higgins‐Chen, Varun B. Dwaraka

Translational Psychiatry · 2025 · ▲ 2 citations

Abstract

Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine's effects on biological aging have not been extensively studied among patients with moderate to severe symptoms of depression and/or trauma. To address this gap, this study looked at the changes in non-epigenetic measures, DNA methylation levels, immune cell composition, and biological age based on various epigenetic biomarkers of aging, of 20 participants at baseline and after completion of a course of six ketamine 0.5 mg/kg infusions in individuals with MDD or PTSD. As expected, depression and PTSD scores decreased in participants following ketamine infusion treatments as measured by the PHQ-9 and PCL-5. We observed a reduction in epigenetic age in the OMICmAge, GrimAge V2, and PhenoAge biomarkers. In order to better understand the changes in epigenetic age, we also looked at the underlying levels of various Epigenetic Biomarker Proxies (EBPs) and surrogate protein markers and found significant changes following ketamine treatment. The results are consistent with existing literature on ketamine's effects on different biomarkers. These results underline the ability of GrimAge V2, PhenoAge, and OMICmAge in particular, to capture signals associated with key clinical biomarkers, and add to the growing body of literature on ketamine's epigenetic mechanisms and their effect on biological aging. Clinical Trial Code. NCT05294835.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1038/s41398-025-03683-y
Canonical
link ↗
Fetched
2026-10-16 MST

Cite this

APA
Dawson, K.L., Carangan, A.M.J.M., Klunder, J., Carreras-Gallo, N., Sehgal, R., Megilligan, S., Askins, B.C., Perkins, N., Mendez, T.L., Smith, R.M., Dawson, M.G., Mallin, M.P., Higgins‐Chen, A., &amp; Dwaraka, V.B. (2025). Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study. <em>Translational Psychiatry</em>. https://doi.org/10.1038/s41398-025-03683-y
Vancouver
Dawson KL, Carangan AMJM, Klunder J, Carreras-Gallo N, Sehgal R, Megilligan S, et al. Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study. Translational Psychiatry. 2025. doi:10.1038/s41398-025-03683-y.
BibTeX
@article{kristin2025Epigen, title = {Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study}, author = {Kristin L. Dawson and Athena May Jean M. Carangan and Jessica Klunder and Natàlia Carreras-Gallo and Raghav Sehgal and Samantha Megilligan and Benjamin C. Askins and Nicole Perkins and Tavis L. Mendez and Ryan M. Smith and Mark G. Dawson and Michael P. Mallin and Albert Higgins‐Chen and Varun B. Dwaraka}, journal = {Translational Psychiatry}, year = {2025}, doi = {10.1038/s41398-025-03683-y}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings